<DOC>
	<DOCNO>NCT01990443</DOCNO>
	<brief_summary>The primary objective study ass absolute bioavailability reslizumab follow administration single subcutaneous ( sc ) dose healthy non-Japanese participant</brief_summary>
	<brief_title>Absolute Bioavailability Reslizumab Healthy Subjects</brief_title>
	<detailed_description>The study design assess pharmacokinetics , safety tolerability , immunogenicity , pharmacodynamics reslizumab</detailed_description>
	<criteria>Criteria Inclusion : Subjects may include study meet follow criterion : All Subjects 1 . Written inform consent obtain . 2 . The subject read , speak , write English Japanese ( applicable respective enrollment group ) . 3 . The subject good health determine medical psychiatric history , physical examination , brief neurologic examination , ECG , serum chemistry , hematology , urinalysis , serology . 4 . The subject , woman , surgically sterile , 2 year postmenopausal , , childbearing potential , use medically accept method contraception , agree continue use method duration study 30 day completion study . Acceptable method contraception include abstinence intrauterine device ( know failure rate le 1 % per year ) . 5 . The subject must willing able comply study restriction remain clinic require duration visit . NonJapanese Subjects 6 . The subject Caucasian parent grandparent . 7 . The subject man woman 18 45 year age body mass index ( BMI ) 20.0 30.0 kg/m2 , inclusive ( Appendix A ) . Note : At least half subject enrol treatment group must within stringent age weight criterion note Japanese subject . Also , every effort make enroll approximately equal number men woman . Japanese Subjects 8 . The subject man woman 20 45 year age weigh 50 80 kg BMI le 28.0 kg/m2 . Note : Every effort make enroll approximately equal number men woman . 9 . The subject born Japan . 10 . The subject Japanese parent grandparent . 11 . The subject live less 5 year outside Japan . 12 . The subject Japanese passport . 13 . The subject plan leave US least 1 week end study . Criteria Exclusion : Subjects exclude participate study meet 1 follow criterion : 1 . The subject clinically significant uncontrolled medical condition ( treat untreated ) . 2 . The subject clinically significant deviation normal ECG , physical examination , brief neurologic examination finding , determine investigator medical monitor . 3 . The subject pregnant lactate woman . ( Any woman become pregnant study withdrawn study . ) 4 . The subject disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ; history appendectomy allow ) . 5 . The subject receive reslizumab previous study . 6 . The subject receive immunosuppressant drug antiinterleukin5 ( antiIL5 ) antibody within 6 month dose study drug . 7 . The subject receive investigational drug ( nonbiologic ) within 30 day 5 halflives ( whichever longer ) dose study drug , case new chemical entity , 3 month 5 halflives ( whichever longer ) dose study drug . 8 . The subject participate investigative biologics study within 6 month 5 halflives ( whichever longer ) dose study drug . 9 . The subject know suspected hypersensitivity idiosyncratic reaction antiIL5 antibody , compound present study drug , monoclonal antibody . 10 . The subject history clinically important drug , vaccine and/or allergy indication potential allergic reaction . Pharmacokinetic StudyHealthy Subjects Clinical Study Protocol Study C38072/1107 8 11 . The subject receive immunization live vaccine within 3 month prior dose study drug immunization live live attenuate vaccine plan within 3 month last dose study drug . 12 . The subject suspect parasitic infestation/infection within 6 month dose study drug . 13 . The subject use vitamin within 2 week dose study drug use systemic topical prescription , nonprescription ( overthecounter [ OTC ] ) medication ( except acetaminophen ibuprofen ) within 2 week 5 halflives ( whichever longer ) dose study drug . 14 . The subject use herbal nutritional supplement within 2 week dose study drug . 15 . The subject donate blood history significant blood loss within 56 day prior dose study drug . 16 . The subject donate plasma within 7 day prior dose study drug . 17 . The subject , rest 5 minute , elevate blood pressure ( define seat systolic blood pressure 140 mm Hg and/or seat diastolic blood pressure 90 mm Hg ) , low blood pressure ( define seat systolic blood pressure le 90 mm Hg and/or seat diastolic blood pressure le 45 mm Hg ) . ( Only 2 rechecks subject 's blood pressure permit eligibility purpose . ) 18 . The subject , rest 5 minute , seat pulse less 45 90 beat per minute ( bpm ) . ( Only 2 rechecks subject 's pulse permit eligibility purpose . ) 19 . The subject , within past 2 year , habitually consume 21 unit alcohol per week , history alcohol , narcotic , substance abuse define Diagnostic Statistical Manual Mental Disorders American Psychiatric Association , Fourth Edition , Text Revision ( DSMIVTR ) ( American Psychiatric Association 2000 ) . Note : For purpose study , unit alcohol equal 1 ounce hard liquor , 5 ounce wine , 8 ounce beer . 20 . The subject positive urine drug screen ( UDS ) alcohol test result . 21 . The subject clinical laboratory test value ( ) outside range ( ) specify , clinically significant laboratory abnormality determine investigator medical monitor : hemoglobin value le 12 g/dL aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 2 time upper limit normal range ( ULN ) total bilirubin 25.7 Î¼mol/L ( 1.5 mg/dL ) 22 . The subject positive test result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) antibodies hepatitis C. 23 . The subject , within 14 day dose study drug , clinically significant excessive consumption coffee , tea , caffeinecontaining beverage food ( ie , 600 mg/day caffeine , 5 cup coffee/day , 10 cup tea/day ) , combination beverage food . 24 . The subject user former user nicotinecontaining product ( include limit cigarette , cigar , chew dip tobacco ) stop use consumption ( ie , smoking , chewing , pinch ) nicotinecontaining product less 12 month study drug administration use used topical oral nicotine preparation smoke cessation within past 3 month study drug administration . 25 . The subject , within 4 week dose study drug , clinically significant illness , within 1 week dose study drug , acute illness , screen day first dose study drug , symptom clinically significant acute illness . 26 . The subject significant active infection ( acute chronic ) within 4 week dose study drug . aa . The investigator feel subject enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Reslizumab</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>